Compare Novo Nordisk A/S (NVO) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs SoundHound AI Inc — how do they compare? Novo Nordisk A/S trades at $46.45 (market cap $207.85B), while SoundHound AI Inc trades at $7.39 (market cap $3.29B). The key difference: Novo Nordisk A/S is far larger — about 63.2× SoundHound AI Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while SoundHound AI Inc pays none. Which is the better fit depends on your goals.
| NVO | SOUN | |
|---|---|---|
Market Cap | $207.85B | $3.29B |
Sector | Health | Technology |
52-Week High | $63.98 | $21.40 |
52-Week Low | $35.29 | $5.70 |
Enterprise Value | $222.55B | $3.09B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
SoundHound AI (SOUN) trades at $7.40, down 0.8% on the day, with strong technical momentum indicated by bullish moving averages. The company shows impressive revenue growth of 45% in Q2 2026 and has beaten earnings expectations for three consecutive quarters. Recent news highlights the proposed LivePerson acquisition and the successful launch of the OASYS platform, which is accelerating enterprise adoption and driving improved guidance.
While growth prospects appear promising with 75% analyst buy ratings and an $8.50 consensus target, significant risks remain including persistent negative margins (-67.45% net income margin), high valuation multiples (P/S 15.31), and substantial cash burn. The stock offers growth potential but requires careful risk management given the premium valuation and path to profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
